Ocugen’s Gene Therapy Trio Nears the Regulatory Finish Line
Veröffentlicht: 01.05.2026 um 06:31 Uhr, Redaktion boerse-global.de
Ocugen is barreling toward a pivotal stretch, with three late-stage gene therapy programs advancing on schedule and a regulatory filing for its lead candidate expected before the end of 2026. The biotech’s stock, however, remains well off its yearly peak, trading at €1.48 — roughly 32% below the March high of €2.17 — even as analysts maintain a unanimous buy rating with an average price target of $9.75.
The company’s most advanced asset, OCU400, targets retinitis pigmentosa, an inherited retinal disease that progressively robs patients of sight. Enrollment for the pivotal Phase 3 trial wrapped up in March, with 140 patients randomized. Ocugen expects initial robust data in early 2027, but the company isn’t waiting for those results before seeking approval. A biologics license application (BLA) is slated for submission to the U.S. Food and Drug Administration in the third quarter of this year, drawing on long-term data from earlier studies that showed vision improvement in the majority of treated patients.
Two other candidates are hot on OCU400’s heels. Dosing in the combined Phase 2/3 trial for OCU410ST, a therapy for Stargardt disease, concluded in April — faster than anticipated. Ocugen aims to make this the first approved treatment for the condition. Meanwhile, OCU410, designed for geographic atrophy, is on track to launch a Phase 3 study in the second half of 2026, following a Phase 2 trial that demonstrated a meaningful slowing of lesion growth.
Should investors sell immediately? Or is it worth buying Ocugen?
Ocugen has been actively showcasing its pipeline on the conference circuit. CEO Shankar Musunuri appeared this week at the Oppenheimer Biotech Summit in Puerto Rico, while Abhi Gupta, Executive Vice President for Commercial and Business Development, spoke simultaneously at the Cell & Gene Meeting on the Mediterranean in Rome. Both presentations highlighted the company’s “gen-agnostic” modifier platform, which aims to correct imbalances across multiple gene networks rather than targeting a single defective gene — a departure from traditional gene therapy approaches.
The company’s financial runway extends into the fourth quarter, thanks to a capital raise in January that replenished its coffers. That should provide enough breathing room to reach the next set of clinical milestones without an immediate cash crunch. Still, the stock has struggled to hold momentum. After sliding in late April on no company-specific news — reflecting broader weakness in small-cap biotech — shares now trade below their 50-day moving average of €1.61. On a 12-month basis, the stock has more than doubled, but the gap between analyst enthusiasm and market reality remains wide.
Ocugen reports first-quarter earnings on May 5. While revenue will draw some attention, the real focus will be on management’s commentary around regulatory timelines. The third quarter looms as the defining moment: if Ocugen can deliver its first BLA on schedule, it will mark the company’s transition from a clinical-stage developer to a commercial contender in the gene therapy space.
Ad
Ocugen Stock: New Analysis - 1 May
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
